A Phase II Study of Ribociclib And Endocrine Treatment of Physician s Choice for Locoregional Recurrent Resected Hormone Receptor Positive HER2 Negative Breast Cancer
- Sponsor:
- Hoosier Oncology Group - HOG
- Sponsor Study ID:
- HCRN BRE20-468
- CTO #:
- 103624
- NCT Number:
- NCT05467891
- Phase:
- II
- Protocol Type:
- Treatment
- Age Group:
- Adults
- Disease Sites:
- Breast
- Study Objectives:
- To estimate subsequent recurrence-free survival at 3 years for ribociclib when administered with ET in patients who hormone receptor positive, HER2 negative breast cancer with adequately resected local recurrence of early breast cancer.
- eConsent:
- Not available
- Study Documents:
-
Open Study Documents
(MUSC NetID required for document access)
For more information about this trial please contact the study team:
-
Medical University of South Carolina
- Principal Investigator, Sivapiragasam, Abirami, at sivapira@musc.edu .
- Study Coordinator, Gelardi, Theresa, at gelardi@musc.edu .
Trial opened at the following institutions:
Medical University of South Carolina